Pfizer Provides Update on Two R&D Pipeline Developments
Pfizer Inc provided updates on two drug candidates in the company's development pipeline:
Capravirine - Pfizer is discontinuing development of capravirine, a non-nucleoside reverse transcriptase inhibitor under study for patients with HIV/AIDS who have failed on currently available antiretroviral therapies. Pfizer based the decision on results of two Phase IIb studies which failed to show a statistically-significant difference between standard triple-drug HIV therapies and the same therapy combined with capravirine. Rights to the compound will be returned to Shionogi & Co Ltd.
Daxas - Pfizer and Altana Pharma have mutually agreed to terminate a collaboration between the two companies involving the development of Daxas (roflumilast), a phosphodiesterase-4 inhibitor for chronic obstructive pulmonary disease (COPD) and asthma. Pfizer is returning all rights to the product candidate to Altana which will assume sole responsibility for the further development of Daxas.
"The search for new and innovative medicines for the treatment of HIV/AIDS, COPD and asthma remains a priority for Pfizer and we will continue to invest in other research activities in these areas to address the needs of patients and health care providers," said John LaMattina, Ph.D., president of Pfizer Global Research and Development.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.